News & Updates
Filter by Specialty:

Does CKD reduce tirzepatide benefits on HFpEF patients with obesity?
Long-term treatment with tirzepatide results in improved renal function in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, regardless of the absence or presence of chronic kidney disease (CKD), according to a post hoc analysis of the SUMMIT trial presented at ACC.25.
Does CKD reduce tirzepatide benefits on HFpEF patients with obesity?
15 Apr 2025
Semaglutide makes STRIDEs in peripheral artery disease
Patients with symptomatic peripheral artery disease and type 2 diabetes see notable improvements in their walking capacity and quality of life with once-weekly semaglutide injections in the phase 3b STRIDE study.
Semaglutide makes STRIDEs in peripheral artery disease
09 Apr 2025
Endocrinologic dysfunction common among CNS infection survivors
Children who survived central nervous system (CNS) infections experience many endocrinologic imbalances, according to a study. Of these infections, meningitis poses the highest risk of subsequent endocrinopathies, particularly short stature.